Oral pharmaceutical composition
A composition and drug technology, applied in the direction of drug combination, drug delivery, active ingredients of heterocyclic compounds, etc., can solve problems such as the stability reduction of cyanocobalamin
Inactive Publication Date: 2020-10-23
来必制药有限公司
View PDF0 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0006] However, there is a problem in this existing pharmaceutical composition that causes the decomposition of cyanocobalamin in the active ingredient, resulting in a greatly reduced stability
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1 to 9
[0063] According to the ingredients and contents shown in Table 1 to Table 3 below, the granules were made into granules through a dry granulation process, and then compressed into single-layer tablets by a tablet machine, so that the pharmaceutical compositions of Examples 1 to 9 were made into tablets. The components of the first active ingredient used in each of Examples 1 to 9 are also organized in Table 4.
[0064] [Table 1]
[0065]
[0066] [Table 2]
[0067]
[0068] [table 3]
[0069]
[0070] [Table 4]: Components of the first active ingredient
[0071]
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The present invention relates to an oral pharmaceutical composition capable of effectively suppressing decomposition of cyanocobalamin, thereby improving stability. The present invention relates to anoral pharmaceutical composition comprising: a first active ingredient comprising adenine or a pharmaceutically acceptable salt thereof, carnitine or a pharmaceutically acceptable salt thereof, a liver extract, a vitamin, and dimethyl biphenyl dicarboxylate; a second active ingredient comprising cyanocobalamin; an alkalizing agent comprising an alkaline organic salt compound or an alkaline inorganic salt compound; and a pharmaceutically acceptable excipient, exhibiting a pH of 5.5 to 9.0 in the state of 7.5% (W / V) aqueous liquid.
Description
technical field [0001] The invention relates to an oral pharmaceutical composition, which can effectively inhibit the decomposition of cyanocobalamin, thereby improving the stability. Background technique [0002] Adenine is one of the purine bases that make up nucleic acids, and is used as a precursor of ATP or ADP, which is used as an energy source in the body, and is also used to form cAMP that participates in cell signaling that occurs in the body. In addition, adenine acts as a neurotransmitter inhibitor in the brain, which can participate in guiding sleep and inhibiting wakefulness (Journal of Alzheimer's Disease 20(2010) S3-S15 S3 DOI10.3233 / JAD-2010-1379), while in the liver Participate in vasoconstriction, increase the breakdown of glycogen into glucose and inhibit fatty liver (Nature 204, 1196-1197 (19December 1964); DOI 10.1038 / 2041196a0). [0003] On the other hand, carnitine is a coenzyme necessary for fatty acid metabolism and has an amino acid derivative stru...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/407A61K9/20A61K47/02A61K47/12A61P1/16A61K31/205A61K31/216A61K31/4415A61K31/52A61K31/525A61K31/714
CPCA61K9/2009A61K9/2013A61K31/205A61K31/216A61K31/4415A61K31/52A61K31/525A61K31/714A61K35/407A61P1/16A61K2300/00A61K9/0053A61K31/14A61K31/225A61K31/513
Inventor 朴孝珍朴叙薰朴相根
Owner 来必制药有限公司
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
